Table 2.
Univariate analysis for patients who received allogeneic HCT for CMML between 2001 and 2012
| Study population (N = 209) | ||
|---|---|---|
| Outcomes | N Eval | Prob (95% CI) |
| Neutrophil engraftment | 206 | |
| 28-day | 92 (88–95)% | |
| 100-day | 97 (95–99)% | |
| Platelet recovery | 207 | |
| 28-day | 66 (59–72)% | |
| 100-day | 86 (81–90)% | |
| Acute GVHD | 209 | |
| 100-day | 36 (30–43)% | |
| Chronic GVHD | 209 | |
| 1-year | 45 (38–52)% | |
| 3-year | 47 (40–54)% | |
| 5-year | 47 (40–54)% | |
| Relapse | 200 | |
| 1-year | 46 (39–53)% | |
| 3-year | 50 (43–57)% | |
| 5-year | 52 (45–59)% | |
| Treatment related mortality | 200 | |
| 1-year | 19 (14–25)% | |
| 3-year | 23 (18–30)% | |
| 5-year | 28 (21–35)% | |
| Disease free survival | 200 | |
| 1-year | 35 (28–42)% | |
| 3-year | 27 (21–33)% | |
| 5-year | 20 (14–27)% | |
| Overall survival | 209 | |
| 1-year | 50 (43–57)% | |
| 3-year | 38 (31–45)% | |
| 5-year | 30 (23–37)% | |